What is the latest WANBURY stock price?
The latest stored price for WANBURY is Rs 339.90 as of 2026-07-20.
gimli
WANBURY stock AI analysis
WANBURY Stock AI Analysis: Price, PE, 50DMA, Shareholding and Peers
WANBURY LIMITED is a small-cap stock in Healthcare. This Gimli page shows the latest available WANBURY price, returns, 50DMA/200DMA trend, PE, ROE, ROCE, financials, shareholding pattern, and industry peers for Indian stock screening research.
Price
₹339.90
1W return
+13.13%
1M return
+27.42%
3M return
+29.81%
6M return
+71.17%
1Y return
+23.98%
Market cap
₹1,187.59 cr
PE
17.96
PB
8.22
ROE
+64.92%
ROCE
+29.68%
RSI
70.26
Turnover
₹15.15 cr
Why it can matter in screens
- Momentum: WANBURY is above 50DMA, above 200DMA; RSI is 70.26.
- Returns: 1D +2.32%, 1W +13.13%, 1M +27.42%, 3M +29.81%, 1Y +23.98%.
- Trend levels: 52W high ₹344.75, 52W low ₹163.34, off high -1.41%.
- Liquidity: latest turnover is ₹15.15 cr; volume vs 20D is +0.59%.
- Valuation/profitability: PE 17.96, PB 8.22, ROE +64.92%, ROCE +29.68%.
- Growth: 3Y sales CAGR +9.28%, 3Y profit CAGR n/a.
Quick Answers
Is WANBURY above its 50DMA and 200DMA?
WANBURY is above 50DMA, above 200DMA. The latest 50DMA is 278.92 and the latest 200DMA is 251.03.
What are WANBURY PE, ROE and ROCE?
WANBURY has PE 17.96, ROE +64.92%, and ROCE +29.68% in Gimli's latest available snapshot.
How has WANBURY performed recently?
WANBURY has returned +27.42% over 1 month, +29.81% over 3 months, and +23.98% over 12 months in the latest stored data.
Is this stock page investment advice?
No. This page is a data snapshot for screening and research. It is not buy, sell, legal, tax, or investment advice.
Financials and Ownership
Quarterly income statement
| Period | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-03-31 | 164.58 cr | 26.45 cr | 21.70 cr | 7.26 |
| 2025-12-31 | 162.45 cr | 26.86 cr | 15.76 cr | 4.52 |
| 2025-09-30 | 160.06 cr | 25.98 cr | 15.18 cr | 4.58 |
| 2025-06-30 | 163.18 cr | 24.79 cr | 13.49 cr | 4.12 |
| 2025-03-31 | 172.00 cr | 31.47 cr | 20.26 cr | 6.18 |
| 2024-12-31 | 133.45 cr | 14.79 cr | n/a | nan |
| 2024-09-30 | 161.19 cr | 21.64 cr | n/a | 2.44 |
| 2024-06-30 | 131.11 cr | 11.92 cr | 1.04 cr | 0.32 |
Annual income statement
| Year | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-03-31 | 650.27 cr | 104.09 cr | 66.13 cr | nan |
| 2025-03-31 | 599.51 cr | 79.91 cr | 30.53 cr | 9.32 |
| 2024-03-31 | 574.48 cr | 98.55 cr | 55.96 cr | 17.10 |
| 2023-03-31 | 498.18 cr | 23.49 cr | -10.40 cr | -3.18 |
| 2022-03-31 | 512.69 cr | 113.19 cr | 81.47 cr | 25.29 |
Balance sheet
| Period | Assets | Cash | Debt | Equity |
|---|---|---|---|---|
| 2026-03-31 | 517.67 cr | 1.61 cr | 224.37 cr | 144.45 cr |
| 2025-03-31 | 413.92 cr | 4.06 cr | 176.91 cr | 59.27 cr |
| 2024-03-31 | 343.12 cr | 3.40 cr | 115.80 cr | 27.94 cr |
| 2023-03-31 | 303.52 cr | 1.49 cr | 108.58 cr | -32.82 cr |
| 2022-03-31 | 352.55 cr | 22.53 cr | 107.66 cr | -23.42 cr |
Cash flow
| Period | OCF | FCF | Cash change |
|---|---|---|---|
| 2026-03-31 | 31.53 cr | -28.08 cr | n/a |
| 2025-03-31 | 26.20 cr | -22.82 cr | n/a |
| 2024-03-31 | 4.70 cr | -12.73 cr | n/a |
| 2023-03-31 | 19.80 cr | 7.17 cr | n/a |
| 2022-03-31 | 40.52 cr | 30.87 cr | n/a |
Shareholding Trend
| Period | Promoter | FII/FPI | DII | MF | Retail | Pledge |
|---|---|---|---|---|---|---|
| 2026-03-31 | +43.02% | +0.59% | +0.00% | +0.00% | +56.39% | +62.18% |
| 2025-12-31 | +43.07% | +0.72% | +0.00% | +0.00% | +56.21% | +62.18% |
| 2025-09-30 | +43.09% | +0.82% | +0.00% | +0.00% | +56.08% | +62.18% |
| 2025-09-18 | +43.09% | +0.82% | +0.00% | +0.00% | +56.08% | +62.18% |
| 2025-06-30 | +39.63% | +1.59% | +0.00% | +0.00% | +58.78% | +76.74% |
| 2025-03-31 | +39.76% | +1.55% | +0.00% | +0.00% | +58.68% | +76.74% |
| 2024-12-31 | +39.76% | +0.84% | +0.00% | +0.00% | +59.40% | +76.74% |
| 2024-09-30 | +39.77% | +1.02% | +0.00% | +0.00% | +59.20% | +76.74% |
| 2024-06-30 | +39.79% | +0.22% | +0.00% | +0.00% | +59.98% | +76.74% |
| 2024-03-31 | +39.79% | +0.18% | +0.00% | +0.00% | +60.03% | +71.05% |
| 2023-12-31 | +39.79% | +0.00% | +0.13% | +0.00% | +60.08% | +76.74% |
| 2023-09-30 | +39.80% | +0.00% | +0.13% | +0.00% | +60.07% | +76.74% |
| 2023-06-30 | +39.84% | +0.00% | +0.13% | +0.00% | +60.03% | +76.74% |
| 2023-03-31 | +39.84% | +0.00% | +0.13% | +0.00% | +60.03% | +76.74% |
| 2022-12-31 | +39.84% | +0.00% | +0.13% | +0.00% | +60.03% | +76.74% |
| 2022-09-30 | +39.85% | +0.00% | +0.13% | +0.00% | +60.02% | +76.74% |
| 2022-06-30 | +39.85% | +0.00% | +0.00% | n/a | n/a | +76.74% |
| 2022-03-31 | +39.89% | +0.00% | +0.00% | n/a | n/a | +76.76% |
| 2021-12-31 | +39.89% | +1.04% | +0.00% | n/a | n/a | +76.76% |
| 2021-09-30 | +39.90% | +0.00% | +0.01% | n/a | n/a | +76.76% |
Industry Peers
| Symbol | Name | Mcap | PE | ROE | 1Y |
|---|---|---|---|---|---|
| SUNPHARMA | SUN PHARMACEUTICAL IND L | 469,405.90 cr | 40.823336 | +14.71% | +15.52% |
| DIVISLAB | DIVI S LABORATORIES LTD | 194,269.92 cr | 75.650281 | +16.19% | +8.71% |
| TORNTPHARM | TORRENT PHARMACEUTICALS L | 169,405.46 cr | 78.319677 | +17.18% | +42.14% |
| APOLLOHOSP | APOLLO HOSPITALS ENTER. L | 128,040.28 cr | 65.380043 | +21.03% | +21.93% |
| CIPLA | CIPLA LTD | 116,452.52 cr | 30.005339 | +11.79% | -2.75% |
| ZYDUSLIFE | ZYDUS LIFESCIENCES LTD | 115,616.29 cr | 23.056854 | +17.93% | +17.85% |
| LUPIN | LUPIN LIMITED | 113,320.96 cr | 21.221472 | +26.83% | +28.27% |
| MAXHEALTH | MAX HEALTHCARE INS LTD | 107,290.40 cr | 74.382732 | +14.33% | -9.32% |
Try these prompts
- Analyze WANBURY with valuation, momentum and industry peers
- Compare WANBURY with other Healthcare stocks
- Show small-cap stocks in Healthcare above 50DMA with positive 1M return
- Find Healthcare stocks with improving momentum and reasonable valuation
Related screen ideas
- View Healthcare stocks
- View small-cap stocks
- Find stocks above 50DMA
- Compare WANBURY with other Healthcare stocks
Data snapshot: 2026-07-20. Not investment advice.